New drug trial aims to help dialysis patients manage dangerous mineral levels

NCT ID NCT00506441

Completed Disease control Sponsor: Tanabe Pharma Corporation Source: ClinicalTrials.gov ↗

Summary

This study tested whether the medication MCI-196 could help control high phosphate levels in people with kidney failure who are on dialysis. The trial involved 245 adult dialysis patients who first received the medication for 12 weeks, then were randomly assigned to continue it or switch to a placebo for 4 weeks. Researchers measured whether the drug effectively lowered phosphate levels compared to placebo.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Study site

Glendale, Arizona, United States
Study site

Tempe, Arizona, United States
Study site

Hot Springs, Arkansas, United States
Study site

Paragould, Arkansas, United States
Study site

Pine Bluff, Arkansas, United States
Study site

Fountain Valley, California, United States
Study site

La Mesa, California, United States
Study site

Long Beach, California, United States
Study site

Lynwood, California, United States
Study site

Orange, California, United States
Study site

San Diego, California, United States
Study site

Whittier, California, United States
Study site

Brandon, Florida, United States
Study site

Hudson, Florida, United States
Study site

Lauderdale Lakes, Florida, United States
Study site

Tampa, Florida, United States
Study site

Augusta, Georgia, United States
Study site

Decatur, Georgia, United States
Study site

Macon, Georgia, United States
Study site

Evanston, Illinois, United States
Study site

Evergreen Park, Illinois, United States
Study site

Fort Wayne, Indiana, United States
Study site

Shreveport, Louisiana, United States
Study site

Springfield, Massachusetts, United States
Study site

Eatontown, New Jersey, United States
Study site

Flushing, New York, United States
Study site

Springfield Gardens, New York, United States
Study site

Allentown, Pennsylvania, United States
Study site

Lewistown, Pennsylvania, United States
Study site

Philadelphia, Pennsylvania, United States
Study site

Columbia, South Carolina, United States
Study site

Orangeburg, South Carolina, United States
Study site

Sumter, South Carolina, United States
Study site

San Antonio, Texas, United States
Study site

Alexandria, Virginia, United States
Study site

Portsmouth, Virginia, United States
Study site

Richmond, Virginia, United States
Study site

West Allis, Wisconsin, United States
Study site

San Juan, Puerto Rico

Conditions

Explore the condition pages connected to this study.

CHRONIC KIDNEY DISEASE DIALYSIS HYPERPHOSPHATEMIA